Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...

Mohammad Ali Sheffeh, MD, from the Mayo Clinic in Rochester, Minnesota, and colleagues examined the efficacy of GLP-1 RA or SGLT-2i initiation for reducing mortality or cardiovascular events among ...

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why ...

"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...

Researchers at the University of Copenhagen have identified a new drug target for weight loss that curbs appetite, boosts ...

Patients who would benefit from a GLP-1 face significant challenges when it comes to access. Shortages have made it difficult ...

Kennedy Jr., who has been tapped by Trump to lead the HHS, has been critical of Ozempic and other weight loss drugs.

CHICAGO — In his presidential address to the American Heart Association on Sunday, Keith Churchwell, a clinical cardiologist ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...